Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients

被引：0
|
作者：
Angell, Helen [1 ]
Ros, Vidalba Rocher [1 ]
Standifer, Nathan [2 ]
Lai, Zhongwu [1 ]
Gresty, Christopher [1 ]
Delord, Jean-Pierre [3 ]
De Jonge, Maja [4 ]
Postel-Vinay, Sophie [5 ]
Italiano, Antoine [6 ]
Krebs, Matthew G. [7 ,8 ]
Kaufman, Bella [9 ]
Park, Yeon Hee [10 ]
Domchek, Susan [11 ]
Herbolsheimer, Pia [12 ]
Hodgson, Darren [1 ]
机构：
[1] AstraZeneca, Cambridge, England
[2] MedImmune, Mountain View, CA USA
[3] Inst Claudius Regaud Oncopole, Toulouse, France
[4] Erasmus MC Canc Inst, Rotterdam, Netherlands
[5] Gustave Roussy Canc Campus, Villejuif, France
[6] Inst Bergonie, Bordeaux, France
[7] Univ Manchester, Manchester, Lancs, England
[8] Christie NHS Fdn Trust, Manchester, Lancs, England
[9] Sheba Med Ctr, Ramat Gan, Israel
[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[11] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[12] AstraZeneca, Gaithersburg, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P257
引用
收藏
页数：2
相关论文
共 50 条
  • [41] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
    Tutt, Andrew Nicholas James
    Kaufman, Bella
    Gelber, Richard D.
    Mc Fadden, Eleanor
    Goessl, Carsten Dietrich
    Viale, Giuseppe
    Arahmani, Amal
    Fumagalli, Debora
    Azim, Hatem Abdel
    Wu, Wenting
    Grocholewicz, Anna
    Costantino, Joseph P.
    Rastogi, Priya
    Garber, Judy Ellen
    Geyer, Charles E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Tutt, A.
    Kaufman, B.
    Garber, J.
    Gelber, R.
    McFadden, E.
    Goessl, C.
    Viale, G.
    Geyer, C.
    Zardavas, D.
    Arahmani, A.
    Fumagalli, D.
    De Azambuja, E.
    Ponde, N.
    Herbolsheimer, P.
    Wu, W.
    Constantino, J.
    Rastogi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Phase II single arm study of durvalumab and olaparib (D plus O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)
    Fujii, T.
    Lipkowitz, S.
    Zimmer, A. D. S.
    Villanueva, E.
    Solarz, B. B.
    Lee, J-M.
    ANNALS OF ONCOLOGY, 2023, 34 : S364 - S364
  • [44] Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
    Blum, Joanne L.
    Laird, A. Douglas
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri H.
    Lee, Kyung-Hun
    Goodwin, Annabel
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Hopkins, Julia F.
    Albacker, Lee A.
    Mina, Lida A.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1383 - 1390
  • [45] Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.
    McCrea, Charles
    Hettle, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)
    Dalvi, T.
    Gelmon, K. A.
    Dent, R.
    Pegram, M.
    Loibl, S.
    Tazir, Y.
    Milner, A.
    Lewis, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
    Robson, Mark
    Ruddy, Kathryn J.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Delaloge, Suzette
    Bannister, Wendy
    Goessl, Carsten
    Degboe, Arnold
    Hettle, Robert
    Conte, Pierfranco
    EUROPEAN JOURNAL OF CANCER, 2019, 120 : 20 - 30
  • [48] Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC)
    Han, J.
    Lim, K. Y.
    Kim, H. Y.
    Han, J. H.
    Oh, S. H.
    Yun, T.
    Kim, H. T.
    Lee, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [50] A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC)
    Rudin, C. M.
    Oliveira, M. R.
    Garon, E. B.
    Bonomi, P.
    Camidge, D. R.
    Nolan, C.
    Busman, T.
    Krivoshik, A.
    Humerickhouse, R.
    Gandhi, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345